Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Trial Details

NCT ID

NCT06710756

Phase

PHASE1 / PHASE2

Sponsor

Perspective Therapeutics

Status

RECRUITING

Cancer Type

Adenocarcinoma Esophageal Cancer

Interventions

[203Pb]Pb-PSV359
[212Pb]Pb-PSV359

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366
Miami, Florida, United States|25.77427,-80.19366
Lexington, Kentucky, United States|37.98869,-84.47772
St Louis, Missouri, United States|38.62727,-90.19789
Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

Aged ≥ 18 years
Satisfactory organ function as determined by laboratory testing
Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1
Life expectancy \> 3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →